Arno Therapeutics, Inc. (ARNI) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Arno Therapeutics, Inc. (ARNI) Healthcare & Pipeline Overview

Arno Therapeutics, Inc. is a biopharmaceutical entity specializing in oncology drug development, advancing pipeline candidates like Onapristone (Phase I/II), AR-12 (Phase I completed), and AR-42 (Phase I investigator-initiated) for various cancers. The company operates with a focused strategy, utilizing strategic licensing and co-development agreements to progress its therapeutic programs.

What Is the Investment Thesis for ARNI?

Arno Therapeutics, Inc. presents an investment thesis centered on its focused pipeline of oncology drug candidates, targeting significant unmet needs in cancer treatment. The company's lead candidate, Onapristone, is in Phase I/II clinical studies for breast, endometrial, and other solid tumors in post-menopausal women, alongside advanced castration-resistant prostate cancer in men. This dual indication strategy for a single asset could potentially broaden its market opportunity upon successful development. Additionally, AR-12, having completed Phase I for solid tumors and hematological malignancies, and AR-42, in Phase I investigator-initiated studies, offer further diversification within its oncology focus. The company's strategic license agreements with institutions like the University of Minnesota and Ohio State University Innovation Foundation, coupled with a co-development agreement with Leica Biosystems, provide external validation and resource leverage for its R&D efforts. While operating with a small team and an early-stage pipeline, successful progression through clinical trials represents a significant value driver, potentially attracting further investment or partnership opportunities in the high-value biotechnology sector.

Based on FMP financials and quantitative analysis

ARNI Key Highlights

Market Capitalization: Arno Therapeutics, Inc. currently holds a market capitalization of $0.00 billion, reflecting its early-stage development and OTC market presence.

• Beta: The company exhibits a Beta of 1.55, indicating higher volatility compared to the broader market, which is common for biotechnology firms with early-stage pipelines.
• Dividend Policy: Arno Therapeutics, Inc. does not currently pay a dividend, consistent with its status as a development-stage biopharmaceutical company focused on reinvesting capital into research and clinical trials.
• Lean Operations: The company operates with a compact team of 4 employees, emphasizing a focused approach to its drug development programs and resource allocation.
• Clinical Pipeline Progress: Key pipeline assets include Onapristone in Phase I/II clinical study, AR-12 having completed Phase I, and AR-42 in Phase I investigator-initiated study, demonstrating active progression in oncology development.

Who Are ARNI's Competitors?

ARNI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ARNI's Key Strengths?

Focused pipeline of three distinct drug candidates (Onapristone, AR-12, AR-42) targeting significant unmet needs in oncology.

• Multiple drug candidates are actively in clinical development (Phase I/II and Phase I), demonstrating ongoing progress.
• Strategic license agreements with reputable institutions like the University of Minnesota and Ohio State University Innovation Foundation provide access to valuable intellectual property.
• AR-12 has potential for diversified application beyond oncology, with pre-clinical studies in anti-microbial targets.

What Are ARNI's Weaknesses?

Very small operational team of 4 employees, which may limit the scope and speed of development activities.

• All pipeline candidates are in early-stage clinical development (Phase I/II or Phase I), implying high risk and long timelines to market.
• Operating on the OTC market, which typically entails lower liquidity and less stringent disclosure requirements compared to major exchanges.
• No current commercialized products, meaning no recurring revenue streams and high reliance on external funding for R&D.

What Could Drive ARNI Stock Higher?

ARNI catalyst: Announcement of further clinical trial results from the Phase I/II study of Onapristone for breast, endometrial, solid tumors, and advanced castration-resistant prostate cancer, expected to provide critical efficacy and safety data.

• Progression of AR-12 into a Phase II clinical study for solid tumors or hematological malignancies, signaling advancement beyond initial safety assessments.
• Release of pre-clinical data or initiation of clinical studies for AR-12 in anti-microbial targets, potentially opening a new therapeutic avenue for the company.
• Continued advancement of AR-42 in its Phase I investigator-initiated clinical study for hematological malignancies and solid tumors, with updates on patient enrollment and preliminary findings.
• Strategic developments or new milestones achieved through existing license agreements with Invivis Pharmaceuticals, Inc., the Regents of the University of Minnesota, and the Ohio State University Innovation Foundation.

What Are the Key Risks for ARNI?

Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.

• Clinical trial failures for any of its pipeline candidates (Onapristone, AR-12, AR-42) could lead to significant delays, increased costs, or complete discontinuation of development programs.
• Significant regulatory hurdles and delays in obtaining necessary approvals from health authorities like the FDA, which are common in the biopharmaceutical industry and can impact market entry timelines.
• High research and development costs associated with advancing multiple drug candidates through clinical trials, without current revenue streams to offset these expenses.
• Intense competition within the oncology drug development market from larger, more established pharmaceutical companies with greater financial and research resources.
• Challenges in securing adequate additional funding or partnerships to sustain ongoing and future clinical development activities, given the company's early stage and small market capitalization.
• Risks inherent to trading on the OTC market, including potential for low liquidity, high price volatility, and limited public disclosure, which can impact investor confidence and stock performance.

What Are the Growth Opportunities for ARNI?

• Growth opportunity 1: Advancement of Onapristone through clinical trials for breast, endometrial, and prostate cancers. Onapristone, a type 1 anti-progestin hormone blocker, is currently in a Phase I/II clinical study. Successful progression through these phases, particularly demonstrating positive efficacy and safety data, could significantly de-risk the asset and increase its valuation. The market for breast, endometrial, and prostate cancers is substantial, with hormone-sensitive variants representing a significant patient population. Positive trial results could lead to accelerated development pathways or attract larger pharmaceutical partners, potentially within a 3-5 year timeline for further clinical milestones.
• Growth opportunity 2: Expansion of AR-12's indications beyond oncology to anti-microbial targets. AR-12, an orally available cancer treatment, has completed Phase I for solid tumors and hematological malignancies. Its concurrent pre-clinical studies for various anti-microbial targets represent a distinct and potentially high-impact growth vector. The global anti-microbial market is vast and constantly evolving due to rising antibiotic resistance, creating a persistent demand for novel agents. Successful pre-clinical and subsequent clinical development in this area could open up entirely new market segments for Arno Therapeutics, diversifying its revenue potential beyond oncology, with initial milestones potentially within 2-4 years.
• Growth opportunity 3: Successful progression and potential commercialization of AR-42 for hematological malignancies and solid tumors. AR-42 is a novel orally available cancer therapy currently in a Phase I investigator-initiated clinical study. The successful completion of this and subsequent clinical phases, demonstrating a favorable risk-benefit profile, would be a critical growth driver. Hematological malignancies and solid tumors collectively represent a large and diverse patient population with ongoing needs for improved treatment options. Positive data could lead to further investment, partnerships, or eventual market entry, with significant clinical milestones expected over the next 3-6 years.
• Growth opportunity 4: Leveraging existing and forging new strategic licensing agreements. Arno Therapeutics currently holds license agreements with Invivis Pharmaceuticals, Inc., the Regents of the University of Minnesota, and the Ohio State University Innovation Foundation. These agreements provide access to intellectual property and research capabilities, which are crucial for a small biopharmaceutical company. Expanding these partnerships or securing new ones for its pipeline candidates could accelerate development, provide non-dilutive funding, and broaden market reach. Such strategic alliances are vital in the biotech sector, potentially enhancing the company's competitive position and pipeline value within a 1-3 year horizon.
• Growth opportunity 5: Capitalizing on the co-development agreement with Leica Biosystems Newcastle Ltd. This co-development agreement suggests a collaborative approach to certain aspects of its product development, potentially related to diagnostics or companion therapies. Successful outcomes from this collaboration could enhance the precision and effectiveness of Arno's therapeutic candidates, making them more attractive to clinicians and patients. Furthermore, such partnerships can streamline development processes and potentially reduce R&D costs. Expanding the scope or achieving key milestones within this co-development framework could contribute to pipeline success and market differentiation over the next 2-5 years.

What Are ARNI's Competitive Advantages?

• Proprietary drug candidates: Onapristone, AR-12, and AR-42 represent unique compounds with specific mechanisms of action targeting various cancers and potentially anti-microbial applications.
• Intellectual property: Patents and regulatory exclusivities associated with its pipeline drugs, if granted, would provide a period of market protection.
• Strategic licensing agreements: Partnerships with Invivis Pharmaceuticals, Inc., the Regents of the University of Minnesota, and the Ohio State University Innovation Foundation provide access to specialized research and intellectual property.
• Co-development expertise: The co-development agreement with Leica Biosystems Newcastle Ltd. indicates specialized collaboration that could enhance product development and differentiation.

What Does ARNI Do?

Arno Therapeutics, Inc. is a biopharmaceutical company headquartered in Flemington, New Jersey, dedicated to the discovery and development of innovative products for the treatment of cancer and other life-threatening diseases. Established with a mission to address significant unmet medical needs in oncology, the company's operational model centers on advancing a targeted pipeline of drug candidates through various stages of clinical development. A cornerstone of its pipeline is Onapristone, a type 1 anti-progestin hormone blocker, which is currently undergoing a Phase I/II clinical study. This candidate is being evaluated for its potential efficacy in treating breast, endometrial, and other solid tumors in post-menopausal women, as well as advanced castration-resistant prostate cancer in men, representing a dual-pronged approach to hormone-sensitive cancers. Further diversifying its therapeutic portfolio, Arno Therapeutics is also developing AR-12, an orally available cancer treatment. AR-12 has successfully completed its Phase I clinical study for solid tumors and hematological malignancies, demonstrating initial safety and tolerability. Beyond oncology, AR-12 is also in pre-clinical studies exploring its potential for various anti-microbial targets, indicating a broader application strategy. The company's pipeline is further strengthened by AR-42, a novel orally available cancer therapy, which is currently in a Phase I investigator-initiated clinical study for the treatment of hematological malignancies and solid tumors. To support its research and development efforts, Arno Therapeutics has established several key strategic collaborations. These include license agreements with Invivis Pharmaceuticals, Inc., the Regents of the University of Minnesota, and the Ohio State University Innovation Foundation, providing access to proprietary technologies and compounds. Additionally, the company maintains a co-development agreement with Leica Biosystems Newcastle Ltd., highlighting its commitment to collaborative innovation in bringing new therapies to market. Operating with a lean team of four employees, Arno Therapeutics focuses its resources on the scientific and clinical progression of its specialized drug candidates.

What Products and Services Does ARNI Offer?

• Develops biopharmaceutical products specifically for the treatment of cancer and other life-threatening diseases.
• Advances Onapristone, a type 1 anti-progestin hormone blocker, through Phase I/II clinical studies for breast, endometrial, and other solid tumors in post-menopausal women.
• Investigates Onapristone for advanced castration-resistant prostate cancer in men.
• Develops AR-12, an orally available cancer treatment, which has completed Phase I clinical study for solid tumors and hematological malignancies.
• Conducts pre-clinical studies for AR-12 to explore its potential as an anti-microbial treatment.
• Advances AR-42, a novel orally available cancer therapy, through Phase I investigator-initiated clinical studies for hematological malignancies and solid tumors.
• Engages in license agreements with academic institutions and pharmaceutical companies to access intellectual property and research capabilities.
• Participates in a co-development agreement with Leica Biosystems Newcastle Ltd. to support product development.

How Does ARNI Make Money?

• Focuses on research and development of novel drug candidates, aiming for future commercialization through direct sales or licensing partnerships.
• Leverages intellectual property from its drug pipeline (Onapristone, AR-12, AR-42) to create therapeutic solutions for oncology and potentially anti-microbial targets.
• Utilizes strategic license agreements with entities like Invivis Pharmaceuticals, Inc., University of Minnesota, and Ohio State University Innovation Foundation to acquire or develop promising compounds.
• Engages in co-development agreements, such as with Leica Biosystems Newcastle Ltd., to share development costs, expertise, and potentially future revenues.
• Relies on successful clinical trial outcomes to attract further investment, secure regulatory approvals, and ultimately generate revenue from drug sales or milestone payments from partners.

What Industry Does ARNI Operate In?

Arno Therapeutics, Inc. operates within the highly specialized and competitive biotechnology industry, specifically focusing on oncology drug development. This sector is characterized by substantial research and development investments, lengthy clinical trial processes, and stringent regulatory hurdles. The global oncology market is projected to continue its robust growth, driven by increasing cancer incidence, advancements in understanding disease mechanisms, and the demand for more targeted and effective therapies. Arno Therapeutics, with its pipeline of Onapristone, AR-12, and AR-42, positions itself as an early-stage player aiming to address specific cancer types, including breast, endometrial, prostate, solid tumors, and hematological malignancies. The competitive landscape includes numerous large pharmaceutical companies and smaller biotech firms, all vying for market share with novel therapies. Arno's strategy of leveraging licensing agreements and co-development partnerships is a common approach for smaller entities to mitigate risk and access broader expertise within this capital-intensive industry.

Who Are ARNI's Key Customers?

• Future patients suffering from breast, endometrial, prostate, solid tumors, and hematological malignancies.
• Healthcare providers, including oncologists and specialists, who would prescribe the company's approved therapies.
• Potentially pharmaceutical companies for licensing or acquisition of drug candidates.
• Research institutions and collaborators for co-development opportunities.

Company Profile

Arno Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Flemington, US. The company is led by CEO David M. Tanen. ARNI has traded publicly since 2008.

Arno Therapeutics, Inc. (ARNI) Valuation Context

Relative to its peer group, ARNI's quantitative score of 48/100 is below the peer average of 76/100.

Return on equity for Arno Therapeutics, Inc. stands at 250.4%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.08 means current liabilities exceed short-term assets, a liquidity point worth watching.

Arno Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

ARNI Financials

ARNI Latest News

No recent news available for ARNI.

ARNI Analyst Consensus

ARNI MoonshotScore

ARNI Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources